SE0000872095
© PR Newswire
05.12.2025
SOBI
LISTED
STO
Sobi to Showcase Scientific advances and Commitment to Haematology at ASH 2025
News Preview
STOCKHOLM, Dec. 5, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced its participation at the 65th American Society of Hematology (ASH) Annual Meeting, taking place on 6 – 9 December in Orlando, Florida. At this year's meeting, Sobi will showcase its commitment to advancing care in haematology with 19 scientific abstracts, including two oral...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2025
SOBI
LISTED
STO
The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of pegcetacoplan for C3G and Primary IC-MPGN
News Preview
Robust and clinically meaningful benefits observed across all three key markers of disease – 68% reduction in proteinuria, stabilisation of kidney function, and substantial clearance of C3 deposits. Consistent results across C3G and primary IC-MPGN, adults and adolescents, and native and post-transplant kidney disease. Pegcetacoplan is under regul...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
SOBI
LISTED
STO
Clinically meaningful pivotal study results for olezarsen in sHTG presented as a late breaker at AHA Scientific Sessions
News Preview
STOCKHOLM, Nov. 8, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that, the TIMI Study Group today has presented positive results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG) at the American Heart Association 2025 Scientific Sessions. The s...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
05.11.2025
SOBI
LISTED
STO
Sobi to present New One-Year Data on pegcetacoplan's efficacy in C3G and primary IC-MPGN and new outcome data on NASP at ASN Kidney Week
News Preview
STOCKHOLM, Nov. 5, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that data on Aspaveli/Empaveli in C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) and NASP in uncontrolled gout will be presented at ASN Kidney Week 2025, 5-9 November in Houston, Texas....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
25.10.2025
SOBI
LISTED
STO
Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions
News Preview
NASP data highlight reduction in disease burden among people living with uncontrolled gout...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2025
SOBI
LISTED
STO
Sobi showcases new data across rare inflammatory conditions at ACR 2025
News Preview
STOCKHOLM, Oct. 24, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), a global biopharmaceutical company dedicated to delivering innovative treatments for patients with rare disease, will be presenting new data across its immunology portfolio at the annual American College of Rheumatology (ACR) Convergence 2025 meeting in...
Themefolio
Profiler
Peergroup
© PR Newswire
21.10.2025
SOBI
LISTED
STO
Change in the Sobi Board of Directors
News Preview
STOCKHOLM, Oct. 21, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), a global biopharmaceutical company today announced that Helena Saxon a member of the Sobi board of Directors, has resigned her position effective immediately. She will be nominated for election to the board of another company which is serving the healthc...
Themefolio
Profiler
Peergroup
© PR Newswire
21.10.2025
SOBI
LISTED
STO
Change in the Sobi Board of Directors
News Preview
STOCKHOLM, Oct. 21, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), a global biopharmaceutical company today announced that Helena Saxon a member of the Sobi board of Directors, has resigned her position effective immediately. She will be nominated for election to the board of another company which is serving the healthc...
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
SOBI
LISTED
STO
Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report
News Preview
STOCKHOLM, Oct. 19, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today a revised full year outlook for 2025 in response to recent developments. As a result of this announcement, Sobi will make adjustments to its financial reporting schedule such that it will announce its th...
Themefolio
Profiler
Peergroup
© PR Newswire
19.10.2025
SOBI
LISTED
STO
Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report
News Preview
STOCKHOLM, Oct. 19, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today a revised full year outlook for 2025 in response to recent developments. As a result of this announcement, Sobi will make adjustments to its financial reporting schedule such that it will announce its th...
Themefolio
Profiler
Peergroup
© PR Newswire
08.10.2025
SOBI
LISTED
STO
Invitation: Sobi's Q3 2025 report
News Preview
STOCKHOLM, Oct. 8, 2025 /PRNewswire/ -- Sobi plans to publish its report for the third quarter of 2025 on 23 October 2025 at 08:00 CEST.
Investors, analysts, and the media are invited to a conference call on the same day at 13:00 CEST, 12:00 BST, and 07:00 EDT. The call will include a presentation...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2025
SOBI
LISTED
STO
New number of shares and votes in Sobi
News Preview
STOCKHOLM, Sept. 30, 2025 /PRNewswire/ -- As per 30 September 2025, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 357,412,837 shares. All shares are common shares. The total number of votes is 357,412,837. The increase in the number of common shares and votes, and the decreas...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
30.09.2025
SOBI
LISTED
STO
New number of shares and votes in Sobi
News Preview
STOCKHOLM, Sept. 30, 2025 /PRNewswire/ -- As per 30 September 2025, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 357,412,837 shares. All shares are common shares. The total number of votes is 357,412,837. The increase in the number of common shares and votes, and the decreas...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2025
SOBI
LISTED
STO
Tryngolza ® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)
News Preview
STOCKHOLM, Sept. 19, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), a global biopharmaceutical company dedicated to delivering innovative treatments for patients with rare diseases, and Ionis Pharmaceuticals, Inc. today announced that Tryngolza® (olezarsen) has been approved in the European Union (EU) as an adjunct to diet in adult patients for the trea...
Themefolio
Profiler
Peergroup
© PR Newswire
10.09.2025
SOBI
LISTED
STO
Invitation: Sobi's NASP and Uncontrolled Gout call and webcast
News Preview
NASP (previously known as SEL-212) - clinical program overview and uncontrolled gout disease landscape.
STOCKHOLM, Sept. 10, 2025 /PRNewswire/ -- Investors, analysts, and members of the media are invited to a conference call on Tuesday, 16 September, at 16:30 CEST, 15:30 BST, and 10:30 EDT. The call will present insights from management and Dr. H...
Themefolio
Profiler
Peergroup
© PR Newswire
29.08.2025
SOBI
LISTED
STO
New number of shares and votes in Sobi
News Preview
STOCKHOLM, Aug. 29, 2025 /PRNewswire/ -- As per 29 August 2025, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 357,412,837 shares, of which 356,000,049 are common shares and 1,412,788 are C-shares. The total number of votes is 356,141,327,8. The increase in the number of shares and votes results from issues of...
Themefolio
Profiler
Peergroup
© PR Newswire
29.08.2025
SOBI
LISTED
STO
New number of shares and votes in Sobi
News Preview
STOCKHOLM, Aug. 29, 2025 /PRNewswire/ -- As per 29 August 2025, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 357,412,837 shares, of which 356,000,049 are common shares and 1,412,788 are C-shares. The total number of votes is 356,141,327,8. The increase in the number of shares and votes results from issues of...
Themefolio
Profiler
Peergroup
© PR Newswire
25.07.2025
SOBI
LISTED
STO
TRYNGOLZA® (olezarsen) recommended for EU approval by CHMP for familial chylomicronemia syndrome (FCS)
News Preview
Recommendation based on Phase 3 Balance results, which showed a significant reduction of triglycerides and substantial reduction of acute pancreatitis events with TRYNGOLZAEuropean Commission decision expected by Q4 2025STOCKHOLM, July 25, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) and Ionis Pharmaceuticals, Inc. today announced that the Committee fo...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.07.2025
SOBI
LISTED
STO
Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP)
News Preview
Doptelet Sprinkle (avatrombopag) was approved as an effective formulation for children one year to less than six years....
Themefolio
Profiler
Peergroup
© PR Newswire
16.07.2025
SOBI
LISTED
STO
Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum
News Preview
STOCKHOLM, July 16, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter 2025
Second Quarter 2025
Total revenue increased 13 per cent, 22 per cent at constant exchange rates, (CER)1, to SEK 6,175 M (5,442)Haematology revenue increased 27 per cent at CER to SEK 4,570 M (3,866), mainly d...
Themefolio
Profiler
Peergroup
© PR Newswire
16.07.2025
SOBI
LISTED
STO
Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum
News Preview
STOCKHOLM, July 16, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter 2025
Second Quarter 2025
Total revenue increased 13 per cent, 22 per cent at constant exchange rates, (CER)1, to SEK 6,175 M (5,442)Haematology revenue increased 27 per cent at CER to SEK 4,570 M (3,866), mainly d...
Themefolio
Profiler
Peergroup
© PR Newswire
15.07.2025
SOBI
LISTED
STO
The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes
News Preview
STOCKHOLM, July 15, 2025 /PRNewswire/ -- The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 8 May 2025, resolved – for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive programmes resolved by the Annual General Meeting – on directed share issues of no more than 1,412,788 red...
Themefolio
Profiler
Peergroup
© PR Newswire
15.07.2025
SOBI
LISTED
STO
The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes
News Preview
STOCKHOLM, July 15, 2025 /PRNewswire/ -- The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 8 May 2025, resolved – for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive programmes resolved by the Annual General Meeting – on directed share issues of no more than 1,412,788 red...
Themefolio
Profiler
Peergroup
© PR Newswire
02.07.2025
SOBI
LISTED
STO
Invitation: Sobi's Q2 report
News Preview
Sobi plans to publish its report for the second quarter of 2025 on 16 July 2025 at 08:00 CEST.
STOCKHOLM, July 2, 2025 /PRNewswire/ -- Investors, analysts, and the media are invited to a conference call on the same day at 14:00 CEST, 13:00 GMT, and 08:00 EST. The call will include a presentation of the results and a Q&A session.
The presenta...
Themefolio
Profiler
Peergroup
© PR Newswire
01.07.2025
SOBI
LISTED
STO
Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)
News Preview
STOCKHOLM, July 1, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce its ex-US royalty obligations to Apellis by 90% for Aspaveli® (systemic pegcetacoplan) in exchange for $275 million upfront and up to $25 million in additional milestone pay...
Themefolio
Profiler
Peergroup
© PR Newswire
01.07.2025
SOBI
LISTED
STO
Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)
News Preview
STOCKHOLM, July 1, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce its ex-US royalty obligations to Apellis by 90% for Aspaveli® (systemic pegcetacoplan) in exchange for $275 million upfront and up to $25 million in additional milestone pay...
Themefolio
Profiler
Peergroup
© PR Newswire
28.06.2025
SOBI
LISTED
STO
FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease
News Preview
Approval based on the pooled analysis of our pivotal EMERALD and NI-0501-06 studies, showing 54% of patients treated with Gamifant achieved complete response at week 8.STOCKHOLM, June 28, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that the U.S. Food and Drug Administration (FDA) approved Gamifant® (emapalumab-lzsg) for the treatment o...
Themefolio
Profiler
Peergroup
© PR Newswire
28.06.2025
SOBI
LISTED
STO
FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease
News Preview
Approval based on the pooled analysis of our pivotal EMERALD and NI-0501-06 studies, showing 54% of patients treated with Gamifant achieved complete response at week 8.STOCKHOLM, June 28, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that the U.S. Food and Drug Administration (FDA) approved Gamifant® (emapalumab-lzsg) for the treatment o...
Themefolio
Profiler
Peergroup
© PR Newswire
20.06.2025
SOBI
LISTED
STO
Sobi will showcase extensive research and clinical outcomes at ISTH 2025
News Preview
STOCKHOLM, June 20, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will be presenting a wide range of clinical study updates at the annual International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington (21-25 June). With ten (10) presentations, Sobi's clinical teams will showcase new data for avatrombopag to treat children with ITP, su...
Themefolio
Profiler
Peergroup
© PR Newswire
12.06.2025
SOBI
LISTED
STO
Sobi share new clinical data across multiple hematologic diseases at EHA 2025
News Preview
STOCKHOLM, June 12, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will present data at the 30th EHA (European Haematology Association) hybrid congress, in Milan, Italy (12-15 June). The congress will feature the latest advances in the treatment of diffuse large B-cell lymphoma (DLBCL), immune thrombocytopenia (ITP), myelofibrosis, paroxysmal nocturnal h...
Themefolio
Profiler
Peergroup
© PR Newswire
06.06.2025
SOBI
LISTED
STO
Sobi and Apellis: Aspaveli®/Empaveli® Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases
News Preview
STOCKHOLM, June 6, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 VALIANT study, investigating Aspaveli® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).The data were presented as p...
Themefolio
Profiler
Peergroup
© PR Newswire
04.06.2025
SOBI
LISTED
STO
Sobi Showcases Breadth of data in C3G/primary IC-MPGN at ERA 2025
News Preview
STOCKHOLM, June 4, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will have a strong scientific presence at this year's ERA congress in Vienna (4-7 June) with a total of eight presentations: six oral presentations and two posters. We are proud that two of our abstracts have been recognised in the top 10 abstracts at ERA 2025, as selected by expert review...
Themefolio
Profiler
Peergroup
© PR Newswire
03.06.2025
SOBI
LISTED
STO
Invitation: Sobi's Aspaveli® - 52-week Phase 3 VALIANT data in nephrology
News Preview
VALIANT Phase 3 data in nephrology after presentation at the ERA congress.
STOCKHOLM, June 3, 2025 /PRNewswire/ -- Investors, analysts, and members of the media are invited to a conference call on Thursday, 12 June, at 13:30 CEST, 12:30 GMT, and 08:30 EDT. The call will include a presentation of results and insights from management and Professor...
Themefolio
Profiler
Peergroup
© PR Newswire
28.05.2025
SOBI
LISTED
STO
Sobi to share new clinical data and research at EULAR 2025
News Preview
STOCKHOLM, May 28, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will present new clinical data and research outcomes at the annual European Congress of Rheumatology (EULAR 2025) in Barcelona from the 11-14 June 2025. Research will include clinical trial outcomes on the efficacy and safety of Gamifant in the treatment of macrophage activating syndrome,...
Themefolio
Profiler
Peergroup
© PR Newswire
08.05.2025
SOBI
LISTED
STO
Bulletin from Sobi's Annual General Meeting (AGM)
News Preview
STOCKHOLM, May 8, 2025 /PRNewswire/ -- The Swedish Orphan Biovitrum AB (publ) (Sobi®) AGM was convened today on 8 May 2025. At the AGM, the shareholders, in accordance with the proposed resolutions, resolved as follows:
Adoption of the profit and loss statements and balance sheet and discharge of liability
The AGM adopted the income statements a...
Themefolio
Profiler
Peergroup
© PR Newswire
08.05.2025
SOBI
LISTED
STO
Bulletin from Sobi's Annual General Meeting (AGM)
News Preview
STOCKHOLM, May 8, 2025 /PRNewswire/ -- The Swedish Orphan Biovitrum AB (publ) (Sobi®) AGM was convened today on 8 May 2025. At the AGM, the shareholders, in accordance with the proposed resolutions, resolved as follows:
Adoption of the profit and loss statements and balance sheet and discharge of liability
The AGM adopted the income statements a...
Themefolio
Profiler
Peergroup
© PR Newswire
29.04.2025
SOBI
LISTED
STO
Sobi publishes Q1 2025 report: Portfolio continues to deliver
News Preview
STOCKHOLM, April 29, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2025
First Quarter 2025
Total revenue increased 3 per cent, 3 per cent at constant exchange rates, (CER)1, to SEK 6,465 M (6,256)Haematology revenue increased 13 per cent at CER to SEK 4,632 M (4,075), mainly driv...
Themefolio
Profiler
Peergroup
© PR Newswire
29.04.2025
SOBI
LISTED
STO
Sobi publishes Q1 2025 report: Portfolio continues to deliver
News Preview
STOCKHOLM, April 29, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2025
First Quarter 2025
Total revenue increased 3 per cent, 3 per cent at constant exchange rates, (CER)1, to SEK 6,465 M (6,256)Haematology revenue increased 13 per cent at CER to SEK 4,632 M (4,075), mainly driv...
Themefolio
Profiler
Peergroup
© PR Newswire
25.04.2025
SOBI
LISTED
STO
Sobi and Sanofi's Foundation S extend partnership with the World Federation of Hemophilia Humanitarian Aid Program
News Preview
Up to five-year contract extension to support the WFH Humanitarian Aid Program with medicine donations and financial assistanceSTOCKHOLM, April 25, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) together with the World Federation of Hemophilia (WFH) and Sanofi, through its philanthropic organisation Foundation S, announced the signing of a contract provi...
Themefolio
Profiler
Peergroup
© PR Newswire
23.04.2025
SOBI
LISTED
STO
Sobi presents clinical data at WFH 2025 Comprehensive Care Summit
News Preview
STOCKHOLM, April 23, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) presents clinical data aimed at updating the global haemophilia community attending this year's WFH 2025 Comprehensive Care Summit in Dubai from the 23 – 25 April. New and updated outcomes and analyses will be presented from the XTEND phase 3clinical program testing the effectiveness of...
Themefolio
Profiler
Peergroup
© PR Newswire
15.04.2025
SOBI
LISTED
STO
Invitation: Sobi's Q1 report
News Preview
STOCKHOLM, April 15, 2025 /PRNewswire/ -- Sobi plans to publish its report for the first quarter of 2025 on 29 April 2025 at 08:00 CET.
Investors, analysts, and the media are invited to a conference call on the same day at 15:30 CET, 14:30 GMT, and 09:30 EST. The call will include a presentation of the results and a Q&A session.
The presenta...
Themefolio
Profiler
Peergroup
© PR Newswire
01.04.2025
SOBI
LISTED
STO
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
News Preview
STOCKHOLM, April 1, 2025 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be held on Thursday, 8 May 2025 at 10.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.
The Board of Directors has decided that sharehol...
Themefolio
Profiler
Peergroup
© PR Newswire
01.04.2025
SOBI
LISTED
STO
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
News Preview
STOCKHOLM, April 1, 2025 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be held on Thursday, 8 May 2025 at 10.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.
The Board of Directors has decided that sharehol...
Themefolio
Profiler
Peergroup
© PR Newswire
31.03.2025
SOBI
LISTED
STO
Sobi publishes Annual and sustainability report for 2024
News Preview
STOCKHOLM, March 31, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) published its Annual and sustainability report today. The report details the progress Sobi has made in 2024 and how Sobi strives to identify and unlock potential breakthrough innovations that transform the lives of people with rare diseases.
Sobi has a strong f...
Themefolio
Profiler
Peergroup
© PR Newswire
31.03.2025
SOBI
LISTED
STO
Sobi publishes Annual and sustainability report for 2024
News Preview
STOCKHOLM, March 31, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) published its Annual and sustainability report today. The report details the progress Sobi has made in 2024 and how Sobi strives to identify and unlock potential breakthrough innovations that transform the lives of people with rare diseases.
Sobi has a strong f...
Themefolio
Profiler
Peergroup
© PR Newswire
19.03.2025
SOBI
LISTED
STO
Sobi announces a new research collaboration on the development of Gamifant® (emapalumab) in sepsis, which is to be presented at the ISICEM congress
News Preview
STOCKHOLM, March 19, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced a research collaboration involving a new Phase 2a clinical trial for Gamifant® (emapalumab) for the potential treatment of interferon-gamma (IFNγ)-driven sepsis (IDS) which is to be presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM...
Themefolio
Profiler
Peergroup
© PR Newswire
27.02.2025
SOBI
LISTED
STO
US FDA grants Priority Review to Sobi's supplemental Biologics Licence Application (sBLA) for Gamifant® (emapalumab-lzsg)
News Preview
STOCKHOLM, Feb. 27, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Gamifant® (emapalumab-Izsg) for use in adult and paediatric patients with hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS)...
Themefolio
Profiler
Peergroup
© PR Newswire
20.02.2025
SOBI
LISTED
STO
EMA validates indication extension application for Aspaveli® for treatment of C3G and primary IC-MPGN
News Preview
STOCKHOLM, Feb. 20, 2025 /PRNewswire/ -- Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are rare, c...
Themefolio
Profiler
Peergroup
© PR Newswire
05.02.2025
SOBI
LISTED
STO
Sobi publishes Q4 2024 report: A solid ending to a strong year
News Preview
STOCKHOLM, Feb. 5, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter 2024.
Fourth Quarter 2024
Total revenue increased 9 per cent, 8 per cent at constant exchange rates, (CER)1, to SEK 7,436 M (6,844)Haematology revenue increased 22 per cent at CER to SEK 4,487 M (3,640), mainly dri...
Themefolio
Profiler
Peergroup
© PR Newswire
05.02.2025
SOBI
LISTED
STO
Sobi publishes Q4 2024 report: A solid ending to a strong year
News Preview
STOCKHOLM, Feb. 5, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter 2024.
Fourth Quarter 2024
Total revenue increased 9 per cent, 8 per cent at constant exchange rates, (CER)1, to SEK 7,436 M (6,844)Haematology revenue increased 22 per cent at CER to SEK 4,487 M (3,640), mainly dri...
Themefolio
Profiler
Peergroup
© PR Newswire
21.01.2025
SOBI
LISTED
STO
Invitation: Sobi's Q4 and FY 2024 report
News Preview
Sobi plans to publish its report for the fourth quarter and full year of 2024 on 5 February 2025 at 08:00 CET.
STOCKHOLM, Jan. 21, 2025 /PRNewswire/ -- Investors, analysts, and the media are invited to a conference call on the same day at 14:30 CET, 13:30 GMT, and 08:30 EST. The call will include a presentation of the results and a Q&A sessio...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2024
SOBI
LISTED
STO
Bulletin from Sobi's Extraordinary General Meeting (EGM)
News Preview
STOCKHOLM, Dec. 11, 2024 /PRNewswire/ -- The Swedish Orphan Biovitrum AB (publ) (Sobi®) EGM was convened today on 11 December 2024. In accordance with the Nomination Committee's proposals, David Meek was elected as new member of the Board of Directors and Chair of the Board of Directors for the period until the end of the Annual General Meeting 2...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2024
SOBI
LISTED
STO
Bulletin from Sobi's Extraordinary General Meeting (EGM)
News Preview
STOCKHOLM, Dec. 11, 2024 /PRNewswire/ -- The Swedish Orphan Biovitrum AB (publ) (Sobi®) EGM was convened today on 11 December 2024. In accordance with the Nomination Committee's proposals, David Meek was elected as new member of the Board of Directors and Chair of the Board of Directors for the period until the end of the Annual General Meeting 2...
Themefolio
Profiler
Peergroup
© PR Newswire
11.11.2024
SOBI
LISTED
STO
Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
News Preview
STOCKHOLM, Nov. 11, 2024 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting (the "Meeting"), to be held on Wednesday, 11 December 2024 at 09.00 at the offices of Mannheimer Swartling Advokatbyrå, Norrlandsgatan 21, Stockholm, Sweden. Registr...
Themefolio
Profiler
Peergroup
© PR Newswire
11.11.2024
SOBI
LISTED
STO
Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
News Preview
STOCKHOLM, Nov. 11, 2024 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting (the "Meeting"), to be held on Wednesday, 11 December 2024 at 09.00 at the offices of Mannheimer Swartling Advokatbyrå, Norrlandsgatan 21, Stockholm, Sweden. Registr...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2024
SOBI
LISTED
STO
David Meek is proposed as new Chair of the Board of Directors of Sobi
News Preview
The Nomination Committee of Swedish Orphan Biovitrum AB (publ) (Sobi®) proposes that David Meek is elected as new Chair of the Board of Directors of Sobi. Sobi intends to convene an Extraordinary General Meeting to be held in December 2024.
STOCKHOLM, Nov. 4, 2024 /PRNewswire/ -- David Meek currently serves as a member of the Board of Directors o...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2024
SOBI
LISTED
STO
David Meek is proposed as new Chair of the Board of Directors of Sobi
News Preview
The Nomination Committee of Swedish Orphan Biovitrum AB (publ) (Sobi®) proposes that David Meek is elected as new Chair of the Board of Directors of Sobi. Sobi intends to convene an Extraordinary General Meeting to be held in December 2024.
STOCKHOLM, Nov. 4, 2024 /PRNewswire/ -- David Meek currently serves as a member of the Board of Directors o...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2024
SOBI
LISTED
STO
New data for emapalumab in the treatment of macrophage activation syndrome to be presented at the ACR conference
News Preview
STOCKHOLM, Oct. 30, 2024 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that new research showing the effect of emapalumab in patients with macrophage activation syndrome (MAS) in Still's disease, including systemic juvenile idiopathic arthritis (sJIA) and adult-onset still's disease (AOSD) who had an inadequate response to high-dose glucocort...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2024
SOBI
LISTED
STO
New data for emapalumab in the treatment of macrophage activation syndrome to be presented at the ACR conference
News Preview
STOCKHOLM, Oct. 30, 2024 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that new research showing the effect of emapalumab in patients with macrophage activation syndrome (MAS) in Still's disease, including systemic juvenile idiopathic arthritis (sJIA) and adult-onset still's disease (AOSD) who had an inadequate response to high-dose glucocort...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2024
SOBI
LISTED
STO
Pivotal VALIANT results presented at Kidney Week show pegcetacoplan treatment effect in patients with C3G / primary IC-MPGN
News Preview
Statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4 All secondary endpoints favoured treatment with pegcetacoplan, including: - Stabilised eGFR, a key measure of kidney function- 71% of patients achieved zero C3c staining intensity, indicating clearance of C3c depositsR...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
